Who is sponsoring NCT03838861?

NCT03838861 is sponsored by University of Southern Denmark.

What drugs are being tested in NCT03838861?

Interventions in NCT03838861: NEMO: NEw MOdel of follow-up.

Is NCT03838861 still recruiting?

NCT03838861 is currently status unknown. Last updated 22 April 2022.

Last reviewed 2022-04-22 · How we verify

NCT03838861: NEMO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Individualised and Patient-centred Follow-up Program for Women With Gynaecological Cancer

Status unknown NA Last updated 22 April 2022

What this trial tests

NA trial testing NEMO: NEw MOdel of follow-up in Empowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROM in 200 participants. Status unknown.

Timeline

1 March 2019

Primary endpoint
31 December 2022

28 January 2025

Quick facts

Lead sponsor	University of Southern Denmark
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	supportive care
Enrollment	200
Start date	1 March 2019
Primary completion	31 December 2022
Estimated completion	28 January 2025
Sites	1 location across Denmark

Drugs / interventions tested

NEMO: NEw MOdel of follow-up

Conditions studied

Empowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROM — all drugs for Empowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROM →

Sponsor

University of Southern Denmark

Who can join

Eligibility, female only, with Empowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROM. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial is testing the hypothesis that an individually focused and need-based nurse led follow-up program supported by electronic Patient Reported Outcome Measures for women with gynecological cancer will improve patient's empowerment, quality of life and involvement in the follow-up process besides reducing the patient's fear of cancer recurrence and degree of psychological distress, compared with a doctor led follow-up program. Further, nurse led follow-up by telephone, may reduce resources of the department as well as of the patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.
Zachou G, El-Khouly F, Dilley J. · · 2023 · cited 8× · PMID 37650760 · DOI 10.1002/14651858.cd006119.pub4
A NEw MOdel of individualized and patient-centered follow-up for women with gynecological cancer (the NEMO study)-protocol and rationale of a randomized clinical trial.
Bergholdt SH, Hansen DG, Johnsen AT, Boman BS, et al · · 2023 · cited 3× · PMID 36726187 · DOI 10.1186/s13063-022-07022-0

Verify or expand the search:

Other University of Southern Denmark trials

Trials by the same sponsor.

NCT07531290 — PeerScreen Trial - Reducing Screen Media Use in Peer-groups of Young People · NA · not yet recruiting
NCT07384273 — Evaluating the Effectiveness of an Internet-based Therapy (iCARE) to Treat Symptoms of Postpartum Depression · NA · recruiting
NCT07426679 — Should Anaesthesiologists Be Taught to Perform Ultrasound-- Assisted Neuraxial Access in Spinal Anaesthesia? · NA · recruiting
NCT07104292 — Pelvic Floor Muscle Training During Pregnancy · NA · recruiting
NCT07194759 — Health Literacy Levels of Patients Living With Type 2 Diabetes and Multi-disease and Their Families Using HLQTM · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03838861 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Southern Denmark
Last refreshed: 22 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03838861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing